Advisor Group Holdings, Inc. G1 Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

$39.8 Billion
Q4 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.2 - $4.98 $1,625 - $3,680	-739 Reduced 7.09%	9,686 $22,000
Q1 2024 May 10, 2024	SELL	$2.1 - $4.83 $24,534 - $56,428	-11,683 Reduced 52.85%	10,425 $45,000
Q4 2023 Feb 12, 2024	BUY	$1.12 - $3.73 $3,389 - $11,286	3,026 Added 15.86%	22,108 $67,000
Q3 2023 Nov 13, 2023	BUY	$1.22 - $2.67 $13,075 - $28,617	10,718 Added 128.14%	19,082 $27,000
Q2 2023 Aug 10, 2023	BUY	$2.46 - $3.14 $8,784 - $11,212	3,571 Added 74.5%	8,364 $20,000
Q1 2023 May 12, 2023	BUY	$2.57 - $8.16 $5,985 - $19,004	2,329 Added 94.52%	4,793 $12,000
Q4 2022 Feb 10, 2023	SELL	$5.19 - $13.5 $30,947 - $80,500	-5,963 Reduced 70.76%	2,464 $13,000
Q3 2022 Nov 14, 2022	BUY	$5.17 - $16.99 $20,266 - $66,600	3,920 Added 86.98%	8,427 $105,000
Q2 2022 Aug 10, 2022	BUY	$4.04 - $8.51 $14,539 - $30,627	3,599 Added 396.37%	4,507 $23,000
Q1 2022 May 04, 2022	SELL	$7.6 - $11.02 $5,532 - $8,022	-728 Reduced 44.5%	908 $193,000
Q3 2021 Nov 05, 2021	SELL	$13.16 - $22.47 $16,581 - $28,312	-1,260 Reduced 43.51%	1,636 $21,000
Q2 2021 Aug 02, 2021	SELL	$19.57 - $26.32 $146,892 - $197,557	-7,506 Reduced 72.16%	2,896 $64,000
Q1 2021 May 13, 2021	BUY	$17.58 - $32.59 $120,264 - $222,948	6,841 Added 192.11%	10,402 $250,000
Q4 2020 Feb 10, 2021	BUY	$10.99 - $20.4 $39,135 - $72,644	3,561 New	3,561 $64,000
Q3 2020 Nov 12, 2020	SELL	$11.55 - $23.75 $7,507 - $15,437	-650 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$9.57 - $24.37 $29,226 - $74,425	-3,054 Reduced 82.45%	650 $15,000
Q1 2020 May 18, 2020	BUY	$9.07 - $26.32 $33,595 - $97,489	3,704 New	3,704 $41,000

Others Institutions Holding GTHX

# of Institutions

Shares Held

3.55M

Call Options Held

11.7K

Put Options Held

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account